Исследование предшественника препарата, нацеленного на рецептор бомбезина, для пептид-рецепторной радионуклидной терапии

Исследование предшественника препарата, нацеленного на рецептор бомбезина, для пептид-рецепторной радионуклидной терапии

Автор: Белобородов Е.А., Юрова Е.В., Сугак Д.Е., Погодина Е.С., Расторгуева Е.В., Саенко Ю.В.

Журнал: Ульяновский медико-биологический журнал @medbio-ulsu

Рубрика: Биологические науки

Статья в выпуске: 3, 2024 года.

Бесплатный доступ

Онкозаболевания - одна из основных причин смерти от болезней во всем мире. Перспективным методом терапии онкопатологии является пептид-рецепторная радионуклидная терапия, в которой доставка терапевтического радионуклида осуществляется с помощью пептидных векторов, способных связываться со специфическими рецепторами на поверхности раковых клеток. Одними из характерных для многих типов рака рецепторов, на которые могут быть нацелены пептидные векторы, являются рецепторы бомбезина. Пептиды, обладая рядом преимуществ, имеют один серьезный недостаток - низкую стабильность в среде организма. Вариантом решения данной проблемы является включение терапевтического пептида в структуру высокостабильного пептида кноттина.

Еще

Онкология, пептид, кноттин, рецептор бомбезина

Короткий адрес: https://sciup.org/14131087

IDR: 14131087   |   DOI: 10.34014/2227-1848-2024-3-126-138

Список литературы Исследование предшественника препарата, нацеленного на рецептор бомбезина, для пептид-рецепторной радионуклидной терапии

  • Sung H., Ferlay J., Siegel R.L. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71 (3): 209-249.
  • Saini K.S., Twelves C. Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. Br J Cancer. 2021; 125 (2): 155-163.
  • Choi H.Y., Chang J.E. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. Int J Mol Sci. 2023; 24 (17): 13618.
  • MerolaE., Grana C.M. Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements. Cancers (Basel). 2023; 15 (11): 2975.
  • Sriram K., Insel P.A. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? Mol Pharmacol. 2018; 93 (4): 251-258.
  • Jensen R.T., Battey J.F., Spindel E.R., Benya R. V. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008; 60 (1): 1-42.
  • Moody T.W., Merali Z. Bombesin-like peptides and associated receptors within the brain: distribution and behavioral implications. Peptides. 2004; 25 (3): 511-520.
  • Ramos-Alvarez I., Moreno P., Mantey S.A. Insights into bombesin receptors and ligands: Highlighting recent advances. Peptides. 2015; 72: 128-144.
  • Gonzalez N., Moody T.W., Igarashi H., Ito T., Jensen R. T. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes. 2008; 15 (1): 58-64.
  • Liolios C., Buchmuller B., Bauder-Wust U. Monomelic and Dimeric 68Ga-Labeled Bombesin Analogues for Positron Emission Tomography (PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors (GRPrs). J Med Chem. 2018; 61 (5): 2062-2074.
  • EngelJ.B., Keller G., SchallyA.V., HalmosG., HammannB., NagyA. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215. Clin Cancer Res. 2005; 11 (6): 2408-2415.
  • Judmann B., Braun D., Wangler B., Schirrmacher R., Fricker G., Wangler C. Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy. Pharmaceuticals (Basel). 2020; 13 (8): 173.
  • Faviana P., Boldrini L., Erba P.A. Gastrin-Releasing Peptide Receptor in Low Grade Prostate Cancer: Can It Be a Better Predictor Than Prostate-Specific Membrane Antigen? Front Oncol. 2021; 11: 650249.
  • Patel O., Shulkes A., Baldwin G.S. Gastrin-releasing peptide and cancer. Biochim Biophys Acta. 2006; 1766 (1): 23-41.
  • Kanashiro C.A., Schally A. V., Nagy A., Halmos G. Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms. Int J Oncol. 2005; 27 (1): 169-174.
  • Moody T.W., Lee L., Ramos-Alvarez I., Iordanskaia T., Mantey S.A., Jensen R.T. Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy. Front Endocrinol (Lausanne). 2021; 1 (12): 728088.
  • Lin Y., Chen T., Zhou M., Wang L., Su S., Shaw C. Ranatensin-HL: A Bombesin-Related Tridecapeptide from the Skin Secretion of the Broad-Folded Frog, Hylarana latouchii. Molecules. 2017; 22 (7): 1110.
  • Vadevoo S.M.P., Gurung S., Lee H.S. Peptides as multifunctional players in cancer therapy. Exp Mol Med. 2023; 55 (6): 1099-1109.
  • Pernot M., Vanderesse R., Frochot C., Guillemin F., Barberi-Heyob M. Stability of peptides and therapeutic success in cancer. Expert Opin Drug Metab Toxicol. 2011; 7 (7): 793-802.
  • Erak M., Bellmann-Sickert K., Els-Heindl S., Beck-Sickinger A.G. Peptide chemistry toolbox - Transforming natural peptides into peptide therapeutics. Bioorg Med Chem. 2018; 26 (10): 2759-2765.
  • Attah F.A., LawalB.A., YusufA.B. Nutritional and Pharmaceutical Applications of Under-Explored Knottin Peptide-Rich Phytomedicines. Plants (Basel). 2022; 11 (23): 3271.
  • Coin I., Beyermann M., Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nature Protocols, 2007; 2 (12): 3247-3256.
  • Zhang H., Qi L., Cai Y., Gao X. Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer. Ann Med. 2024; 56 (1): 2320301.
  • Mant C.T., Chen Y., Yan Z., Popa T.V., Kovacs J.M., Mills J.B., Tripet B.P., Hodges R.S. HPLC analysis and purification of peptides. Methods Mol Biol. 2007; 386: 3-55.
  • Moore S.J., Leung C.L., Norton H.K., Cochran J.R. Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging. PLoS One. 2013; 8 (4): 60498.
  • Lumiprobe.com. URL: https://ru.lumiprobe.com/protocols/nhs-ester-labeling (дата обращения: 11.02.2024).
  • Bradley C.A. [177Lu]PSMA-617 radionuclide therapy shows promise. Nat Rev Urol. 2018; 15 (8): 468.
  • Ferguson S., Wuest M., Richter S., Bergman C., Dufour J., Krys D., Simone J., Jans H.S., Riauka T., Wuest F. A comparative PET imaging study of 44gSc- and 68Ga-labeled bombesin antagonist BBN2 derivatives in breast and prostate cancer models. Nucl Med Biol. 2020: 90-91: 74-83.
  • D'Huyvetter M., Xavier C., Caveliers V., Lahoutte T., Muyldermans S., DevoogdtN. Radiolabeled nano-bodies as theranostic tools in targeted radionuclide therapy of cancer. Expert Opin Drug Deliv. 2014; 11 (12): 1939-1954.
  • Pernot M., Vanderesse R., Frochot C., Guillemin F., Barberi-Heyob M. Stability of peptides and therapeutic success in cancer. Expert Opin Drug Metab Toxicol. 2011; 7 (7): 793-802.
  • Li X., Cai H., Wu X., Li L., Wu H., Tian R. New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer. Front Chem. 2020; 1 (8): 583309.
  • Ariki N.K., Muñoz L.E., Armitage E.L., Goodstein F.R., George K.G., Smith V.L., Vetter I., Herzig V., King G.F., Loening N.M. Characterization of Three Venom Peptides from the Spitting Spider Scytodes thoracica. PLoS One. 2016; 11 (5): 0156291.
  • Jiang L., Kimura R.H., Miao Z. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. J Nucl Med. 2010; 51 (2): 251-258.
  • Ischia J., Patel O., Bolton D., Shulkes A., Baldwin G.S. Expression and function of gastrin-releasing peptide (GRP) in normal and cancerous urological tissues. BJU Int. 2014; 113 (2): 40-47.
  • Chave H.S., Gough A.C., Palmer K., Preston S.R., Primrose J.N. Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa. Br J Cancer. 2000; 82 (1): 124-130.
  • Pooja D., Gunukula A., Gupta N., Adams D.J., Kulhari H. Bombesin receptors as potential targets for anticancer drug delivery and imaging. Int J Biochem Cell Biol. 2019; 114: 105567.
  • Rurarz B.P., UrbanekK.A., Karczmarczyk U., Raczkowska J., Habrowska-Górczynska D.E., KozieiM.J., Kowalska K., Kadiubowski S., Sawicka A., Maurin M., Piastowska-Ciesielska A.W., Ulanski P. Towards Cancer Nanoradiopharmaceuticals-Radioisotope Nanocarrier System for Prostate Cancer Theranostics Based on Radiation-Synthesized Polymer Nanogels. Cancers (Basel). 2023; 15 (23): 5646.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp